Ipamorelin and sermorelin both stimulate growth hormone release. However, they do so through completely different receptor systems. Sermorelin has a significantly longer regulatory and human research history. It also carries a documented side effect profile—raising cortisol and prolactin in certain formulations—that ipamorelin was specifically designed to avoid.
Ipamorelin vs Sermorelin — key differences
The fundamental mechanistic difference between these two compounds is profound and worth understanding clearly. Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It activates the GHRH receptor on the pituitary gland — the same general pathway used by CJC-1295, discussed elsewhere in this series. Ipamorelin activates a completely separate receptor, the ghrelin receptor (GHS-R1a). This places it in a distinct category of growth hormone-releasing peptides (GHRPs) [1], [2]. This distinction in mechanism has real-world consequences for how each compound behaves and what research exists for it.
Sermorelin has a much longer and more established regulatory history than ipamorelin. It was previously approved by the FDA for diagnostic use in evaluating growth hormone deficiency in children, before being later withdrawn from the US market by the manufacturer. This gives it a documented, though now expired, prior approval status that ipamorelin never had [3].
Sermorelin also has more extensive human studies specifically in ageing populations. A notable randomised, placebo-controlled trial analysed a closely related GHRH analogue, chemically equivalent to the active compound of sermorelin, over five months in men and women aged 55–71 years. It showed that nocturnal subcutaneous administration significantly increased both growth hormone release within two hours of each injection and mean 12-hour growth hormone levels at both week 4 and week 16 of treatment, in both sexes. It did not produce significant changes in the underlying frequency or amplitude of the body's natural growth hormone pulses [4].
By contrast, the most significant human clinical trial for ipamorelin was conducted in a completely different context: post-operative gastrointestinal recovery, rather than in an ageing or wellness-focused population. This means that a direct comparison of „results” between the two compounds in similar study populations is not really possible with the currently available data [5].
Regarding safety selectivity, ipamorelin has a clear, well-documented advantage. Its primary pharmacological studies specifically showed that it does not significantly raise cortisol or ACTH, even at very high doses. This distinguishes it from older-generation GHRP compounds [1].
Sermorelin, acting via the GHRH pathway rather than the ghrelin pathway used by ipamorelin, was not developed with this specific selectivity concern in mind. GHRH analogues generally were not associated at all with the cortisol-raising effect seen in some older GHRP compounds. This means it is not so much an advantage of ipamorelin over sermorelin as a difference in what problem each compound was designed to solve.
| Feature | Ipamorelin | Sermorelin |
|---|---|---|
| Mechanism | Ghrelin receptor (GHS-R1a) agonist [1], [2] | GHRH receptor agonist [3] |
| Regulatory History | Never approved by the FDA | Previously approved by the FDA for diagnostic use in children; later withdrawn from the US market |
| Effect on GH pulse frequency/amplitude | Triggers a single, dose-dependent pulse upon administration [6] | No significant change in pulse frequency or amplitude in the ageing population study [4] |
| Effect on cortisol/ACTH | It does not significantly raise either of them, even at high doses [1] | It wasn't a specific design goal; the GHRH pathway is generally not associated with this effect |
| Context of the most significant human study | Post-operative gastrointestinal recovery [5] | Age-related restoration of GH/IGF-1 [4] |
| Half-life | ~2 hours [6] | ~11–12 minutes [7] |
| Effects on appetite | Animal studies show increased food intake and fat mass via a ghrelin-related mechanism [8] | Not associated with appetite stimulation |
What is better? What the evidence actually supports
Declaring one of these compounds definitively „better” than the other is not well supported by evidence. No published study has directly compared ipamorelin and sermorelin in the same study. Each has a different type of research behind it, rather than one simply outperforming the other on common measures. Sermorelin's advantage lies in its longer history. It has a prior history of FDA approval, even if currently lapsed for this specific use. It was also tested in a dedicated, multi-month, placebo-controlled study specifically in an ageing population. This gives it a bit more real-world context for the anti-aging and wellness use cases for which both compounds are commonly discussed today [3], [4].
The advantage of ipamorelin lies specifically in its selectivity profile. The well-documented lack of a cortisol or ACTH response, even at high doses, is a truly valuable pharmacological feature with no equivalent in terms of the same kind of dedicated demonstration in sermorelin studies [1].
Countering ipamorelin, however, are animal studies discussed elsewhere in this series. They show that ipamorelina can actually increase appetite and body fat through its ghrelin receptor mechanism [8]. This is a documented concern that has no equivalent in the sermorelin literature reviewed here.
Given the diverse contexts in which each compound has been studied, and the total lack of direct comparative studies, a fair position is this. It is a choice between two different mechanisms with distinct documented strengths and gaps—not a case where one compound has been shown to outperform the other on the same measured outcome metric.
Limitations of current evidence
No published human study has directly compared ipamorelin and sermorelin with each other. This means that this comparison reflects the separate evidence base of each compound rather than the controlled result of a direct comparison.
Data from the sermorelin study in the ageing population provide really useful context [4]. However, they involved a related association of a GHRH analogue and a specific study population, not a direct test against ipamorelin.
The discovery of the cortisol selectivity of ipamorelin is well documented [1]. However, its discoveries from animal studies regarding appetite and fat gain represent a real and concrete caveat absent from the sermorelin literature [8].
Disclaimer
Neither ipamorelin nor sermorelin is currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general therapeutic, anti-aging, or performance-related use in humans. Sermorelin previously held FDA approval for a specific diagnostic indication in children, which has since been withdrawn from the US market. Neither compound is manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals for general use. The information in this article is based on published data from clinical and pharmacological studies, and does not establish that either compound is safe or effective for general anti-aging, wellness, or performance purposes. This article is provided solely for general educational and informational purposes, reflects the state of published scientific literature at the time of writing, and does not constitute medical advice. Nothing in this article should be used to choose, combine, or self-administer any compound.
References
[1] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Veldhuis, J. D., & Bowers, C. Y. (2010). Integrating GHS into the ghrelin system. International Journal of Peptides, 2010, Article 879503. https://doi.org/10.1155/2010/879503
[3] Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: History, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25–37. https://doi.org/10.1002/rco2.9
[4] Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1–29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
[5] Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[6] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[7] Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: History, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25–37. https://doi.org/10.1002/rco2.9
[8] Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065